International Journal of Medical Research & Health Sciences
  • Year: 2019
  • Volume: 8
  • Issue: 4

Sero-epidemiological profile of markers of hepatitis b viral infection in cancer patients at the Yaounde General Hospital

  • Author:
  • Sorelle-Hemerode Mbock1, Kagoue Simeni Luc-Aime12,, Paul Talla3, Jean-Thierry Ebogo Belobo4, Etienne Atenguena Okobalemba3, Aurelie Hapi Tchuisseu1, Loubou Mohamadou Lawan15, Sabine Dooh Ngalle1, Yengo Clauvis Kunkeng6, Erwin Ngatcha Tatchou1, Michel Kengne1
  • Total Page Count: 7
  • Page Number: 175 to 181

1School of Health Sciences, Unite of Microbiology-Immunology, Catholic University of Central Africa, Yaounde, Cameroon

2Faculty of Health Sciences, University of Buea, Buea, Cameroon

3Yaounde General Hospital, Yaounde, Cameroon

4Institute of Medical Research and Medicinal Plant Study, IMPM, Yaounde, Cameroon

5Agence Nationale de la Radio-Protection, ARNP, Yaounde, Cameroon

6Department of Biochemistry, University of Yaounde, Yaounde, Cameroon

*Corresponding e-mail: simenikagus@yahoo.fr

Online published on 1 October, 2020.

Abstract

Hepatitis B virus (HBV) infection is a public health issue worldwide. In Cameroon, its seroprevalence-was 11.2% in 2018. However, data specific to cancer patients is missing and the risk of reactivation of viral hepatitis B in patients treated for cancer is not negligible. The objective of this study was to determine the seroepidemiological profile of markers of viral hepatitis B infection in cancer patients at the Yaounde General Hospital (HGY).

This cross-sectional study was conducted from March 2018 to December 2018. Total of 244 cancer patients was recruited from the HGY Oncology Department. Hepatitis B viral markers (HBs Antigen, HBe, and HBc Antibody, Anti-HBs, Anti-HBe) were determined by immunochromatographic assay (On Site HBV-5 rapid test) in serum samples of patients.

Total 28 men (11.48%) and 216 women (88.52%) were recruited. The average age was 44.07 ± 1.57 years old. The majority of patients had breast cancer (77.05%), 24/244 patients had HBsAg positive (9.84%), 32/244 anti-HBc positive (13.11%), 32/244 anti-HBe positive (13.11%) and 64/244 anti-HBs positive (26.23%), 4/244 patients had acute hepatitis (1.64%), 20/244 patients were inactive carriers (8.20%), 20/244 were cured (8.20%), 48/244 were immunized by vaccination (19.67%) and 152/244 were free from hepatitis B (62.30%).

HBV testing should be performed in patients scheduled for cancer chemotherapy and those tested negative should be advised to join the vaccination programme. About 8.2% of patients are at a risk for reactivation of hepatitis when receiving chemotherapy.

Keywords

Hepatitis B, Cancer, Reactivation, Sero-epidemiological